Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Gao M, Gao J, Xie L, Wu G, Chen W, et al.
…icacy data are lacking for bedaquiline used with background regimens to treat Chinese TB patients. Here, we describe our initial clinical experience for bedaquiline treatment of a large multicentre cohort of MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) patients in …
О. А. Пискунова, Л. В. Панова, E. S. Ovsyankinа, E. A. Krushinskaya
…b> To study the safety of bedaquiline (Bdq) in chemotherapy regimens for MDR/XDR TB patients. <b>Materials and methods:</b> We conducted a cohort prospective study of 35 patients aged 13-18 years with MDR/XDR pulmonary TB in 2016-2020. The indications for Bdq administration were:…
Lupien A, Vocat A, Foo CS, Blattes E, Gillon JY, et al.
…uggesting that MCZ could be added to different TB treatment regimens without any significant adverse effects.
Nataliya Stavitskaya, Sergey Smerdin, D.A. Kudlay, Н. П. Докторова, Osiet Tlif, et al.
<b>Method:</b> Due to the widespread increase of XDR TB and the lack of choice of effective drugs, chemotherapy of these patients is a serious problem. The efficacy of treatment of XDR TB patients ranges from 29 to 33%. <b>Purpose:</b> Evaluation of therapeutic effectiveness of b…
O. S. Ilyina, Sergey Smerdin, М. А. Плеханова, М. В. Вершинина, E. M. Desyatskova, et al.
…minomethylpyridinium perchlorate (Tpp) to anti-tuberculosis regimens during the intensive phase of treatment of pulmonary tuberculosis patients with MDR, pre-XDR and XDR. Subjects and Methods. Group Tpp+ consisted of 72 patients who completed a course of anti-tuberculosis therapy…
Gao JT, Du J, Wu GH, Pei Y, Gao MQ, et al.
Background World Health Organization recommends countries introducing new drug and short treatment regimen for drug resistant tuberculosis (DR-TB) should develop and implement a system for active pharmacovigilance that allows for detection, reporting and management of adverse eve…
Derek T Armstrong, Emma C E Baird, Logan Pretty, Karen D'Agostino, Matthew Schwartz, et al.
…erculosis (TB) cases in the United States (US). The current regimens for TB treatment rely on knowing resistance patterns to optimize treatment, and missed resistance could have a negative impact on the health of the patient, as well as contribute to increased drug-resistance mut…
Dara, Masoud, Gozalov, Ogtay, World Health Organization. Regional Office for Europe
…aspects of the implementation of new tuberculosis drugs and regimens” co-organized with the Laboratories, Diagnostics and Drug-resistance team of the Global TB Programme (GTB). The objective of the rGLC/Europe meeting and following workshop were to discuss uptake of current WHO p…
Paikray E, Das P, Pattnaik M, Mishra V
Background and objectives Tuberculosis (TB) is an airborne contagious illness caused by Mycobacterium tuberculosis . Ineffective anti-TB medication prolongs and exasperates illness, promotes disease spread, increases the probability of developing resistance to treatment, and incr…
Feng Ding, Sinian Li, Xiangxiang Liu, Guoju Shao, Youfeng Su, et al.
…as to evaluate the efficacy of bedaquiline (Bdq)-containing regimens in pre-extensively drug-resistant tuberculosis (pre-XDR-TB) patients in Shenzhen, China, and to investigate the association between Bdq resistance and unfavorable outcomes. **METHODS:** Data were collected from…
Naidoo K, Naidoo A, Abimiku AG, Tiemersma EW, Gebhard A, et al.
Introduction The TriAD study will assess the Xpert MTB/XDR (Xpert XDR; Cepheid) assay to detect tuberculosis (TB) drug resistance in sputum testing positive for TB to rapidly triage and treat patients with a short all-oral treatment regimen. Methods and analysis In this study, ap…
Fu L, Xiong J, Wang H, Zhang P, Yang Q, et al.
…and better mimic real-world conditions. Patients' treatment regimens are initially based on drug resistance profiles and patient's preference, and later, treatment-responsive cases are randomized to different treatment durations. Alongside, a single-arm trial is being conducted t…
Wenrui Ding, Lingyun Shen, Ruonan Li, Xiaotao Yang, Yanchun Wang, et al.
Drug-resistant tuberculosis (TB) is a significant global challenge, especially in children, where diagnosis and treatment are difficult. This report describes a 4-month-old male infant with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) successfully treated with bedaqui…
Sahak Mkrtchyan
Extensively drug-resistant tuberculosis (XDR-TB) presents a significant therapeutic challenge due to resistance to both first-line and several second-line anti-tuberculosis drugs. Treatment planning becomes even more complex when psychiatric comorbidities and drug hypersensitivit…
Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Tiberi S, et al.
…tuberculosis (TB) cases treated with bedaquiline-containing regimens undergoing surgery. Methods This retrospective observational study recruited patients treated for TB in 12 centres in 9 countries between January 2007 and March 2015. Patients who had surgical indications in a b…
Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, et al.
South African patients with rifampicin-resistant tuberculosis (TB) and resistance to fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) were granted access to bedaquiline through a clinical access programme with strict inclusion and exclusio…
Auchynka V, Kumar AMV, Hurevich H, Sereda Y, Solodovnikova V, et al.
…omes and post-treatment recurrence) of delamanid-containing regimens among adults (>18 years) with MDR-TB or XDR-TB from June 2016 to February 2018. This was a nationwide cohort study involving analysis of routinely collected programme data from the national and six regional TB h…
Forson A, Kwara A, Kudzawu S, Omari M, Otu J, et al.
… resistance is a major challenge to the use of standardized regimens for tuberculosis (TB) therapy, especially among previously treated patients. We aimed to investigate the frequency and pattern of drug resistance among previously treated patients with smear-positive pulmonary t…
Qi Nie, Yuan Liu, Fan Xiao, Yong Zhou, Tingting Fu, et al.
**BACKGROUND:** Management of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) during pregnancy poses a formidable clinical challenge, particularly when complicated by tuberculous meningoencephalomyelitis (TBMEM), While the WHO operational handbook provides a general fram…
Yutong Wang, Leiwen Fu, Zhili Li, Yuhong Liu, Liang Li
…s, marked drug toxicity, and poor patient compliance. While regimens containing new drugs (bedaquiline, delamanid) have substantially improved MDR/RR-TB outcomes, systematic research on the epidemiological characteristics and risk control of adverse drug reactions (ADRs) remains …
Pontali E, Raviglione MC, Migliori GB
Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20-24 months), toxicity, costs and sub-optimal outcomes.After over 40 years of neglect, two new drugs…
Maretbayeva SM, Rakisheva AS, Adenov MM, Yeraliyeva LT, Algozhin YZ, et al.
Rifampicin-resistant/multidrug-resistant (RR/MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis (TB) are serious public health problem in Kazakhstan. In 2012 and 2013, stringent regulatory authorities approved the first new TB drugs in fifty years, bedaquiline a…
Barvaliya SV, Desai MK, Panchal JR, Solanki RN
Aims Bedaquiline (BDQ) has been recently approved for drug resistant tuberculosis with active drug safety monitoring under programmatic condition. The present study was conducted to evaluate safety, tolerability and efficacy of bedaquiline plus optimised background regimen. Metho…
В.А. Шорохова, O.G. Komissarova, A. M. Tikhonov, R.Yu. Abdullaev
The article describes a clinical observation illustrating a rational approach to the correction of adverse drug-induced reaction – severe toxic polyneuropathy in a patient with extensively-drug resistant (XDR) infiltrative pulmonary TB with cavities and dissemination – during adm…
S Koirala, Nayab Shah, Prajjwal Pyakurel, Manish Khanal, Sagar Kumar Rajbhandari, et al.
SETTING: Nine drug-resistant TB centres, some of them supported by Damien Foundation in Nepal where >80% of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) patients are treated. OBJECTIVE: To assess the uptake, effectiveness and safety of the 9-12-month shorter treatment …